413 related articles for article (PubMed ID: 21677471)
21. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
[TBL] [Abstract][Full Text] [Related]
23. [Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib].
Jost D; Stroszczynski C; Chmelik P; Gaffke G; Schlecht I; Pink D; Reichardt P; Schneider U; Hohenberger P; Felix R
Rofo; 2003 Jun; 175(6):791-8. PubMed ID: 12811692
[TBL] [Abstract][Full Text] [Related]
24. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
25. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
26. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
27. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
28. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
Catani M; De Milito R; Simi M
Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
[TBL] [Abstract][Full Text] [Related]
29. Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.
Burandt E; Schreiber M; Stein A; Minner S; Clauditz TS; Bokemeyer C; Jänicke F; Fisch M; Izbicki JR; Knecht R; Sauter G; Stahl PR
Genes Chromosomes Cancer; 2014 Mar; 53(3):228-39. PubMed ID: 24311521
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
32. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
33. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
Neuzillet C; de Mestier L; Rousseau B; Mir O; Hebbar M; Kocher HM; Ruszniewski P; Tournigand C
Pharmacol Ther; 2018 Jan; 181():49-75. PubMed ID: 28723416
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
Roukos DH
Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
[TBL] [Abstract][Full Text] [Related]
35. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
[TBL] [Abstract][Full Text] [Related]
36. The role of targeted therapy for gastrointestinal tumors.
Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
[TBL] [Abstract][Full Text] [Related]
37. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
38. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
39. Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms.
Bellizzi AM
Semin Diagn Pathol; 2013 Nov; 30(4):329-61. PubMed ID: 24342289
[TBL] [Abstract][Full Text] [Related]
40. Bespoke treatment: drivers beware!
Pattison S; Zalcberg JR
Asia Pac J Clin Oncol; 2014 Dec; 10(4):378-80. PubMed ID: 25155963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]